GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 19 Dec 2016.
Interleukin 33
IL-33, interleukin-33
IL33 (MIM 608678) is a member of the IL1 (see MIM 147760) family that potently drives production of T helper-2 (Th2)-associated cytokines (e.g., IL4; MIM 147780). IL33 is a ligand for IL33R (IL1RL1; MIM 601203), an IL1 family receptor that is selectively expressed on Th2 cells and mast cells (summary by Yagami et al., 2010 [PubMed 20926795]).[supplied by OMIM, Jan 2011] (from
NCBI)
Turnquist et al., Pittsburgh, United States. In Curr Opin Organ Transplant, Feb 2016
PURPOSE OF REVIEW: The purpose of this review is to provide a general update on recent developments in the immunobiology of IL-33 and IL-33-targeted immune cells.
Locksley et al., San Francisco, United States. In Nature, Feb 2016
Experiments in mice and humans have demonstrated requirements for the epithelial cytokines IL-33, thymic stromal lymphopoietin (TSLP) and IL-25 in the activation of ILC2s, but the sources and regulation of these signals remain poorly defined.
Benschop et al., Indianapolis, United States. In Cytokine, Feb 2016
IL-33 effects are mediated through its receptor, ST2 and IL-1RAcP, and its signaling induces the production of a number of pro-inflammatory mediators, including TNFα, IL-1β, IL-6, and IFN-γ.
Hvid et al., Århus, Denmark. In Springerplus, Dec 2015
Interleukin-33 is a relatively newly described cytokine, which holds a promising potential as a biomarker for different diseases including atopic dermatitis.
Falcone et al., Milano, Italy. In J Diabetes Res, Dec 2015
In particular, we show that VSL#3 treatment inhibits IL-1β expression while enhancing release of protolerogenic components of the inflammasome, such as indoleamine 2,3-dioxygenase (IDO) and IL-33.
Takenaga et al., Izumo, Japan. In Cell Death Dis, Dec 2015
The proinflammatory interleukin-33 (IL-33) binds to its receptor ST2L on the surface of immune cells and stimulates the production of Th2 cytokines; however, the effects of IL-33 on tumour cells are poorly understood.
Wang et al., Cincinnati, United States. In Immunity, Nov 2015
Herein, we have reported the identification of multifunctional IL-9-producing mucosal mast cells (MMC9s) that can secrete prodigious amounts of IL-9 and IL-13 in response to IL-33, and mast cell protease-1 (MCPt-1) in response to antigen and IgE complex crosslinking, respectively.
Rudensky et al., New York City, United States. In Cell, Sep 2015
This tissue repair modality is mobilized in Treg cells in response to inflammatory mediator IL-18 or alarmin IL-33, but not by TCR signaling that is required for suppressor function.
Hampl et al., Praha, Czech Republic. In Physiol Res, 2014
Among all reviewed cytokines, the most promising are CSF IL-10 and IL-33, enabling to follow-up the disease progression and monitoring the effectiveness of the shunt insertion.
Atamas et al., Baltimore, United States. In J Immunol, 2012
Full-length interleukin (IL)-33 is functionally active in vivo in an IL-1 receptor-like 1 (ST2)-independent fashion, and its effects are partially different from those of mature IL-33.
Kwon et al., Ulsan, South Korea. In J Immunol, 2012
The priming effect of IL-33 occurs during multiple steps of the neutrophil-mediated anti-fungal response: first, rapid induction of neutrophils to the site of the infection, and second, conditioning of neutrophils by IL-33.
Kwon et al., Seoul, South Korea. In Biochem Biophys Res Commun, 2012
data provide the first evidence that IL-33 in the nucleus of endothelial cells participates in inflammatory reactions as a transcriptional regulator of NF-kappaB p65.